KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 38.81%.

  • Pfizer's EBITDA Margin rose 33100.0% to 38.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.55%, marking a year-over-year increase of 507000.0%. This contributed to the annual value of 27.98% for FY2024, which is 175600.0% up from last year.
  • Per Pfizer's latest filing, its EBITDA Margin stood at 38.81% for Q3 2025, which was up 33100.0% from 34.48% recorded in Q2 2025.
  • Pfizer's EBITDA Margin's 5-year high stood at 47.01% during Q3 2022, with a 5-year trough of 410.16% in Q4 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 35.6% (2021), whereas its average is 22.31%.
  • As far as peak fluctuations go, Pfizer's EBITDA Margin plummeted by -2380700bps in 2023, and later skyrocketed by 2331600bps in 2024.
  • Quarter analysis of 5 years shows Pfizer's EBITDA Margin stood at 32.77% in 2021, then skyrocketed by 39bps to 45.45% in 2022, then plummeted by -1002bps to 410.16% in 2023, then skyrocketed by 109bps to 35.5% in 2024, then rose by 9bps to 38.81% in 2025.
  • Its EBITDA Margin was 38.81% in Q3 2025, compared to 34.48% in Q2 2025 and 36.15% in Q1 2025.